Synopsis of new antiangiogenetic factors, mutation compensation agents, and monoclonal antibodies in target therapies of breast cancer
Grammatikakis, I.; Zervoudis, S.; Kassanos, D.
Journal of BUON Official Journal of the Balkan Union of Oncology 15(4): 639-646
2010
ISSN/ISBN: 1107-0625 PMID: 21229623 Document Number: 639310
Breast cancer is the most common type of cancer among females and the 5th most common cause of cancer death. About 5-10% of breast cancers occur due to gene mutations inherited from mother or father. The molecular basis of breast cancer has been extensively investigated, making gene therapy a potential new therapeutic alternative. Mutation compensation, molecular chemotherapy, proapoptotic gene therapy, antiangiogenic gene therapy, genetic immunopotentiation and genetic modulation of resistance/sensitivity are the main gene therapies used. The combination of gene therapy with chemotherapy or radiation is being investigated in ongoing trials. The purpose of this review was to make a synopsis of the currently existing target therapies in breast cancer.